MediBuddy
MediBuddy runs India's largest telehealth platform, linking corporate insurance to doctors and hospitals.
On the record
Checkpoint: Independent FY26 RoC filing expected to confirm or contradict the company's claimed Q4 EBITDA-positive quarter
The call
MediBuddy has the network and insurance ties to keep operating, but its path to real profit is still unverified and richer rivals are already selling against it.
MediBuddy connects patients to doctors and hospitals through an app and website, plus handles insurance paperwork for companies. It built a real advantage by signing up tens of thousands of doctors and thousands of hospitals over years, which is hard and expensive to copy, and AI chatbots cannot fully replace doctors. But Tata 1mg, Reliance, and Apollo are all bigger companies that can spend more money to build similar doctor networks and undercut MediBuddy's prices, and the company hasn't raised new investor money in three years. The one thing that would prove MediBuddy can survive is if it actually starts making real profit (not just accounting profit) while big rivals do not steal away its corporate customers with cheaper deals.
Why
01
AI pressure: ChatGPT and Gemini style health assistants. General AI chatbots could absorb basic symptom checks, but MediBuddy's own CLARA bot shows it's automating that layer itself rather than losing it. Could AI do the core job? Only partly.
02
Bigger players: Tata 1mg, Reliance/Netmeds, Apollo 24/7. These conglomerate backed rivals already run competing telehealth apps with far deeper pockets, pressuring pricing on corporate wellness contracts. Could a giant copy it? Yes, easily.
03
What protects it. A built out network of 90,000+ doctors, 7,000+ hospitals, and 5,000+ corporate insurance workflow integrations that took years to wire up.
What would change this call
Independent RoC filing for FY26 confirms or contradicts Q4 EBITDA-positive claim. Shows whether MediBuddy's profitability is real or just a press release.
MediBuddy closes a fresh equity round in the next 6 to 9 months. Shows investors still back it against better-capitalized rivals.
Tata 1mg or Reliance/Netmeds announce aggressive corporate-wellness pricing or client wins. Shows incumbents are actively taking corporate-insurance share from MediBuddy.
MediBuddy closes a fresh equity round in the next 6 to 9 months. Shows investors still back it against better-capitalized rivals.
Tata 1mg or Reliance/Netmeds announce aggressive corporate-wellness pricing or client wins. Shows incumbents are actively taking corporate-insurance share from MediBuddy.
Key numbers
- FY25 revenue ₹724.6 Cr, up 12.3% YoY from ₹645.4 Cr
- FY25 EBITDA margin improved to -14.19% from -25.67%
- Company claims Q4 FY26 EBITDA positive, ₹1,500 Cr run-rate
Named risks
- Q4 FY26 EBITDA-positive claim is company press release only, unverified by independent RoC filings.
- No confirmed new equity round since August 2023 despite competitive capital needs.
- Conglomerate-backed rivals Tata 1mg and Reliance Netmeds have deeper balance sheets to contest corporate insurance accounts.
- Revenue growth decelerated sharply from over 100% YoY in FY24 to 12.3% in FY25.
- Low-value triage and consultation volume exposed to free consumer generative AI health assistants.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Tata 1mg (Tata Digital) | contesting | Deeper balance sheet than MediBuddy, active in e-pharmacy and consultations as of 2026 |
| Reliance Netmeds | contesting | Reliance Retail-backed pharmacy delivery competing directly for MediBuddy's corporate accounts |
| Apollo 24/7 (Apollo Hospitals) | contesting | Hospital-backed digital arm with physical network advantage as of 2026 |
| PharmEasy (API Holdings) | contesting | Competes in e-pharmacy and diagnostics segment overlapping with MediBuddy's offerings |
| Practo | contesting | Direct competitor in doctor discovery and consultations since 2008 founding |
Questions people ask
- Is MediBuddy profitable in 2026?
- MediBuddy claims its first EBITDA-positive quarter in Q4 FY26, announced May 18, 2026, with an annualized revenue run-rate over Rs 1,500 Cr, per its own press release. This figure is company-claimed and not yet confirmed by independent RoC filings, which typically surface later in the year.
- Who is MediBuddy's biggest competitor?
- MediBuddy faces conglomerate-backed rivals Tata 1mg (Tata Digital), Netmeds (Reliance Retail), and Apollo 24/7 (Apollo Hospitals), all with deeper balance sheets. As of FY25, MediBuddy's revenue growth slowed to 12.3% YoY (Rs 724.6 Cr), down sharply from prior-year doubling, per Entrackr, December 23, 2025.
- Could AI replace MediBuddy's consultations?
- MediBuddy already automates triage internally via its own CLARA chatbot, per medibuddy.ai (2024). Low-value symptom-checking is exposed to free consumer AI assistants, but prescriptions, lab logistics, and its 5,000+ corporate insurance integrations require licensed clinicians and physical networks AI cannot replicate.
- Has MediBuddy raised new funding recently?
- MediBuddy's last confirmed funding was an $18M equity infusion from Quadria Capital, Lightrock, and TEAMFund in August 2023, plus a Rs 70 Cr (~$8.4M) debt round from Alteria Capital/InnoVen in May 2024. No new equity round has been confirmed since, per Inc42 (2026-05-28).
- What is MediBuddy's revenue and is it growing?
- MediBuddy posted Rs 724.6 Cr (~$87M) operating revenue in FY25, up 12.3% from Rs 645.4 Cr in FY24, per Entrackr, December 23, 2025. Growth decelerated sharply from FY24's more than 100% YoY increase, signaling a shift from growth-at-all-costs toward margin discipline.
- Who owns MediBuddy?
- MediBuddy, legally Phasorz Technologies Private Limited, is privately held and venture-backed, with no IPO or parent acquisition. Key investors include Quadria Capital and Lightrock India, who led its $125M Series C round on February 24, 2022, valuing the company at approximately $302M.
Timeline
- 2026-05-18Company claims first EBITDA-positive quarter, Rs 1,500 Cr annualized revenue run-rate
- 2025-12-23FY25 revenue reported at Rs 724.6 Cr, up 12.3% YoY, losses narrowed 37%
- 2024-05-28Raised Rs 70 Cr (~$8.4M) debt from Alteria Capital and InnoVen Capital
- 2023-10-22CEO Satish Kannan guided full profitability target for FY25
- 2023-08-01Raised $18M equity infusion from existing investors for M&A
- 2023-01-21Laid off about 200 employees (8% of workforce) after DocsApp merger consolidation
- 2022-07-13Acquired rural healthtech startup Clinix
- 2022-02-24Raised $125M Series C led by Quadria Capital and Lightrock India, valuation ~$302M
- 2020-01DocsApp merged with diagnostics platform MediBuddy, brand consolidated by December 2022
- 2013-01Founded as DocsApp by Satish Kannan and Enbasekar Dinadayalane
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37% (2025-12-23)
- MediBuddy Annual Revenue Runrate Rises To INR 1500Cr, Records Strong Profit in Q4 FY'26 (2026-05-18)
- Health-tech startup MediBuddy eyes profit in FY25 (2023-10-22)
- MediBuddy Stock Price, Funding, Valuation, Revenue & Financial Statements (2025-04-07)
- India's Largest Digital Healthcare Company MediBuddy Raises USD 125 Million in Series C Funding (2022-02-24)
- MediBuddy Gets Fresh Capital Boost Of $18 Million From Existing Investors (2026-07-28)
- MediBuddy Funding 2026, Total Funding, Rounds & Investors (2026-05-28)
- Valuation, Funding Rounds & Stock Price (2026-02-28)
- Lightrock India-Backed MediBuddy Lays Off Around 200 Employees (2023-01-21)
- MediBuddy Acquisitions 2026, Companies Acquired & Highlights (2026-05-28)
- How MediBuddy became India's largest on-demand, full-stack digital health care platform (2024-11-23)
- Is It Worth It? (2026 Review) (2026-05-23)